Kanna Health
Kadence Bio (formerly Kanna Health) is a UK-based, clinical-stage life sciences company developing KH-001 as the first FDA-approved pharmaceutical treatment for premature ejaculation, alongside a pipeline of mood disorder therapeutics. It serves adult males with PE and patients with mood disorders, and is currently pre-revenue.
- Company typePrivate
- Founded2021
- HeadquartersSevenoaks, United Kingdom
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Kanna Health does
Kadence Bio (formerly Kanna Health) is a clinical-stage life sciences company founded in 2021 and headquartered in Sevenoaks, United Kingdom, developing novel therapeutics for sexual and mental health conditions. Its lead asset, KH-001, is being advanced as the first FDA-approved pharmaceutical treatment for premature ejaculation, an indication with no currently approved drug therapy. Phase 1 safety studies for KH-001 were completed successfully in Q3 2024, and the company has continued to publish preclinical evidence supporting the candidate's mechanism, most recently in April 2026. Beyond KH-001, the company maintains a pipeline of compounds targeting mood disorders, positioning it across two adjacent therapeutic verticals.
The company operates with a founder-led team of 11-50 employees, with John Boghossian as CEO, Ryan Protzko as President, and Lars Wilde as Chairman. To date it has raised approximately $9.96M across two funding rounds (October 2021 and May 2022) from a syndicate including re.Mind Capital, Wilde Ventures, WPSS.bio, Ayuh Ventures, Empath Ventures, Globivest, Neo Kuma Ventures, and Palo Santo Fund. It was selected for the Zcube-Zambon Research Venture's Open Accelerator in September 2024 and obtained B-Corp certification in May 2024, reflecting an ESG-oriented brand posture consistent with its consumer-adjacent therapeutic positioning.
As a pre-revenue clinical-stage developer, Kadence Bio has no commercialized products or active distribution channels. Its intended revenue model upon regulatory approval is traditional prescription pharmaceutical product sales for KH-001 (PE) and future pipeline assets (mood disorders), with no pricing or licensing terms currently disclosed. The company is primarily engaging the market through educational content marketing, LinkedIn presence, and earned media to build category awareness around premature ejaculation and mental health.
Kanna Health firmographics
Firmographics- Name
- Kanna Health
- Website
- https://kanna.health
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kadence Bio (formerly Kanna Health) is a UK-based, clinical-stage life sciences company developing KH-001 as the first FDA-approved pharmaceutical treatment for premature ejaculation, alongside a pipeline of mood disorder therapeutics. It serves adult males with PE and patients with mood disorders, and is currently pre-revenue.
- Ownership category
- akta.pro rank
Kanna Health industry classification
Industry- Product category
- Pharmaceutical Therapeutics
- NAICS
- Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where Kanna Health is headquartered
LocationHeadquarters
- HQ city
- Sevenoaks
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Kanna Health business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue clinical-stage company. Upon FDA approval, the company plans to commercialize KH-001 as a prescription therapeutic for premature ejaculation, with additional compounds in development for mood disorders. Revenue model will likely be traditional pharmaceutical product sales through prescription channels.
Go-to-market motion1 record
Marketing channels4 records
Kanna Health product offering
Product offeringCore offering
Kanna Health (now operating as Kadence Bio) is a clinical-stage life sciences company developing novel therapeutics derived from the kanna plant. Its lead asset, KH-001, is being advanced through FDA clinical trials as the first FDA-approved pharmaceutical treatment for premature ejaculation, with Phase 1 safety studies completed in Q3 2024. The company also maintains a pipeline of compounds targeting mood disorders including depression and anxiety.
Product overview
Kadence Bio (formerly Kanna Health) is a clinical-stage life sciences company developing novel therapeutics rather than a traditional tech product. The company's core offering consists of pharmaceutical drug candidates, with KH-001 as the lead asset targeting premature ejaculation. The company also maintains a pipeline of compounds targeting mood disorders. This is a biopharmaceutical portfolio focused on sexual and mental health therapeutics, not a software or technology platform product.
Differentiator
Problem solved
Functional benefit
Products and services
- KH-001 Lead therapeutic asset being developed as the first FDA-approved pharmaceutical treatment for premature ejaculation (PE) in adult males. Phase 1 safety studies completed successfully in Q3 2024, with subsequent clinical trials planned before potential commercial launch. Targets the significant unmet medical need for PE, a condition with no FDA-approved pharmaceutical treatments currently available.
- Mood Disorder Pipeline Compounds Pipeline of novel compounds targeting mood disorders including depression and anxiety, addressing significant unmet therapeutic needs in mental health. These compounds represent the company's secondary development program alongside the lead KH-001 asset for premature ejaculation.
Quantifiable outcome
- Phase 1 safety studies completed successfully
Companies that use Kanna Health
Customer profileSegments2 records
Ideal customer profiles2 records
Kanna Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Kanna Health partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Zcube-Zambon Research VenturecoreKadence Bio was selected for Zcube-Zambon Research Venture's Open Accelerator program in September 2024. This partnership provides access to research venture resources, potential funding, mentorship, and strategic support for advancing the company's therapeutic development programs in sexual and mental health.
Scale indicators1 record
Recent moves7 records
Expansion highlights5 records
Kanna Health competitors and assessment
Company assessmentDirect peers
- Ixchelsis: UK-based clinical-stage pharmaceutical company developing novel therapies for premature ejaculation and other sexual health conditions. Most direct comparable to Kadence Bio given shared focus on first-in-class PE therapeutics for similar patient populations.
- Futura Medical: UK-based specialty pharmaceutical company developing innovative sexual health products, including Eroxon for erectile dysfunction. Comparable as a clinical-to-commercial sexual health therapeutics developer targeting similar patient demographics.
- Compass Pathways: Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Comparable as a similarly-sized clinical-stage biotech pursuing novel mechanisms for mood disorders — a key part of Kadence Bio's pipeline strategy.
- MindMed: Clinical-stage mental health company developing psychedelic-inspired therapies for anxiety, depression, and other CNS conditions. Comparable in therapeutic area, stage, and novel-mechanism approach to Kadence Bio's mood disorder pipeline.
- ATAI Life Sciences: Clinical-stage biopharmaceutical company developing transformative treatments for mental health, including depression and anxiety. Comparable as a clinical-stage platform company pursuing novel CNS mechanisms similar to Kadence Bio's mood disorder pipeline.
Broad incumbents
- Sage Therapeutics: Established CNS-focused biopharmaceutical company that developed Zurzuvae (zuranolone) for postpartum depression. Comparable as a developer of novel CNS therapeutics addressing mood and mental health indications overlapping with Kadence Bio's pipeline.
- Pfizer: Global pharmaceutical company that markets dapoxetine (Priligy) for premature ejaculation in many ex-US markets. Comparable as the most established player in PE therapeutics and a potential strategic acquirer or competitor to KH-001.
- Boehringer Ingelheim: Global pharmaceutical company with a longstanding urology and sexual health franchise. Comparable as a broad incumbent with strategic interest in sexual health therapeutics and the commercial infrastructure that Kadence Bio would need post-approval.
Emerging players
- BioXcel Therapeutics: Clinical-stage biopharmaceutical company applying AI to develop transformative medicines in neuroscience and immuno-oncology. Comparable as a small-cap clinical-stage CNS therapeutics developer operating with a similar capital and headcount profile to Kadence Bio.
- Marinus Pharmaceuticals: Clinical-stage pharmaceutical company developing therapeutics for seizure disorders and other CNS conditions. Comparable as a similarly-sized clinical-stage CNS drug developer with a focus on underserved neurological indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Kanna Health social profiles
Digital presenceKanna Health compliance and trust
Trust signalCompliance1 record
Kanna Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kanna Health leadership team
Management profileNumber of profiles
Profiles3 records
Kanna Health funding detail
Funding detailFunding overview
Funding rounds2 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kanna Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kanna Health
What does Kanna Health do?
Kanna Health (now operating as Kadence Bio) is a clinical-stage life sciences company developing novel therapeutics derived from the kanna plant. Its lead asset, KH-001, is being advanced through FDA clinical trials as the first FDA-approved pharmaceutical treatment for premature ejaculation, with Phase 1 safety studies completed in Q3 2024. The company also maintains a pipeline of compounds targeting mood disorders including depression and anxiety.
Is Kanna Health a public or private company?
Kanna Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kanna Health founded?
Kanna Health was founded in 2021. It employs 11 to 50 people.
Where is Kanna Health based?
Kanna Health is headquartered in Sevenoaks, United Kingdom, in the Europe region.
How does Kanna Health make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Kanna Health's main competitors?
Direct peers on record are Ixchelsis, Futura Medical, Compass Pathways, MindMed and ATAI Life Sciences. Broad incumbents are Sage Therapeutics, Pfizer and Boehringer Ingelheim. Emerging players are BioXcel Therapeutics and Marinus Pharmaceuticals.
Does Kanna Health have an API?
No public API is recorded for Kanna Health.
What industry is Kanna Health in?
Kanna Health's product category is Pharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325411 and its SIC code is 2834.